Treatment of Interstitial Lung Disease
For idiopathic pulmonary fibrosis (IPF), use nintedanib or pirfenidone as first-line antifibrotic therapy; for connective tissue disease-associated ILD, start with mycophenolate as the preferred immunosuppressant; for progressive pulmonary fibrosis (PPF) despite standard management, add nintedanib; and for rapidly progressive ILD, initiate high-dose intravenous glucocorticoids combined with rituximab or cyclophosphamide.
Idiopathic Pulmonary Fibrosis (IPF)
Antifibrotic therapy with nintedanib or pirfenidone is the cornerstone of IPF treatment, slowing annual FVC decline by approximately 44-57% 1. Both agents have demonstrated similar efficacy in reducing disease progression and are conditionally recommended based on high-quality evidence 2.
- Nintedanib: An oral tyrosine kinase inhibitor that blocks fibrogenic pathways
- Pirfenidone: An oral agent with anti-inflammatory, antioxidative, and antiproliferative effects
Key caveat: Avoid glucocorticoids and immunosuppressants in IPF—they provide no benefit and increase harm 2.
Connective Tissue Disease-Associated ILD (CTD-ILD)
First-Line Treatment Hierarchy
Mycophenolate is the preferred first-line agent across all CTD-ILD subtypes based on favorable efficacy and safety profile 3. The 2024 ACR/CHEST guidelines establish a clear treatment hierarchy:
Preferred options:
- Mycophenolate (top choice for all CTD-ILD)
- Rituximab
- Azathioprine
- Cyclophosphamide
Additional options for specific diseases:
- Tocilizumab: For systemic sclerosis-ILD (SSc-ILD) and mixed connective tissue disease-ILD (MCTD-ILD) 3
- JAK inhibitors: For inflammatory myopathy-ILD (IIM-ILD) 3
- Calcineurin inhibitors: For IIM-ILD 3
Glucocorticoid Use in CTD-ILD
For systemic sclerosis-ILD, strongly avoid glucocorticoids due to increased risk of scleroderma renal crisis, particularly at doses >15 mg/day prednisone equivalent 3.
For other CTD-ILD subtypes, short-term glucocorticoids (≤3 months) may be conditionally used, but long-term use is recommended against 3.
Antifibrotic Therapy in CTD-ILD
Nintedanib is conditionally recommended for SSc-ILD as first-line therapy 3. For other CTD-ILD subtypes (Sjögren's disease, IIM, MCTD), nintedanib is conditionally recommended against as first-line treatment but may be considered for progressive disease 3.
Pirfenidone is conditionally recommended against for CTD-ILD as first-line therapy 3.
Progressive Pulmonary Fibrosis (PPF)
PPF is defined as meeting ≥2 of 3 criteria within the past year in non-IPF ILD: worsening symptoms, radiological progression, and physiological progression (FVC decline) 2.
Treatment Approach
Nintedanib is conditionally recommended for PPF after failure of standard management (conditional recommendation, low-quality evidence) 2. The INBUILD trial demonstrated efficacy in slowing FVC decline across various ILD subtypes manifesting PPF 2.
Pirfenidone requires further research for PPF—the guideline committee could not reach consensus, with 38% abstaining due to insufficient evidence 2. Two small trials (253 patients with fibrotic unclassifiable ILD and 127 patients with PPF) were terminated early or showed very low-quality evidence 2.
Disease-Specific Considerations for Progression
For CTD-ILD with progression despite first-line therapy:
- Switch to or add: mycophenolate, rituximab, cyclophosphamide, or nintedanib 3
- For RA-ILD progression: Conditionally recommend adding pirfenidone 3
- For SSc-ILD progression: Consider referral for stem cell or lung transplantation 3
- For IIM-ILD progression: Add JAK inhibitors or calcineurin inhibitors 3
Critical decision point: The choice between nintedanib versus immunosuppression depends on the pace of progression and extent of fibrotic disease (particularly UIP pattern on CT) 3.
Hypersensitivity Pneumonitis
Antigen identification and avoidance is the primary intervention 4. When antigen avoidance fails to improve clinical status, initiate prednisolone 4.
For progressive fibrotic hypersensitivity pneumonitis meeting PPF criteria, nintedanib is conditionally recommended 2.
Sarcoidosis
Most patients with pulmonary sarcoidosis do not require treatment 4. Initiate anti-inflammatory drugs (prednisolone) or immunosuppressants when:
- Symptomatic pulmonary involvement progresses
- Critical extrapulmonary involvement (cardiac, neurologic, ocular) is present 4
For progressive fibrotic sarcoidosis meeting PPF criteria, consider nintedanib after standard therapy failure 2.
Cryptogenic Organizing Pneumonia
While not explicitly addressed in the provided guidelines, this typically responds to glucocorticoids. The general principle is to use immunosuppression for inflammatory ILD patterns.
Rapidly Progressive ILD (RP-ILD)
For RP-ILD, immediately initiate high-dose intravenous methylprednisolone combined with aggressive immunosuppression 3:
Combination therapy approach:
- Triple therapy (for confirmed/suspected anti-MDA-5 antibody): IV glucocorticoids + 2 additional agents
- Double therapy (without MDA-5): IV glucocorticoids + 1 additional agent
Preferred additional agents:
- Rituximab
- Cyclophosphamide
- Calcineurin inhibitors
- JAK inhibitors
- IVIG (if infection concern)
- Mycophenolate 3
Critical action: Consider early lung transplant referral for RP-ILD 3.
Exception for SSc with RP-ILD: No consensus on glucocorticoid use due to renal crisis risk; if used, monitor closely and keep dose minimal 3.
Monitoring and Supportive Care
Regular monitoring should include:
- Symptom assessment
- Pulmonary function tests (FVC decline ≥5% over 12 months indicates 2-fold increased mortality) 1
- High-resolution CT imaging 4, 5
- 6-minute walk test 1, 6
Non-pharmacological interventions:
- Structured exercise/pulmonary rehabilitation: Improves 6-minute walk distance and quality of life 1, 6
- Supplemental oxygen: For patients desaturating <88% on 6-minute walk test 1
- Lung transplant evaluation: For end-stage disease (median survival 5.2-6.7 years post-transplant vs <2 years without) 1
Common Pitfalls
- Using immunosuppression in IPF: This causes harm without benefit—only antifibrotics are appropriate 2
- High-dose glucocorticoids in SSc-ILD: Increases scleroderma renal crisis risk, particularly >15 mg/day 3
- Delaying antifibrotic therapy in PPF: Once progression is documented, standard immunosuppression alone may be insufficient 2
- Missing RP-ILD: Requires immediate aggressive combination therapy, not stepwise escalation 3
- Combining antifibrotics with mycophenolate upfront: Not recommended; use sequentially rather than simultaneously 3